Caspases and neuroprotection

Current Opinion in Investigational Drugs

Volumn 3, Issue 12, 2002, Pages 1745-1752

  Bilsland, James ^a   Harper, Sarah ^a  

^a Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

Apoptosis; Caspases; Ischemia; Neurodegeneration; Parkinson's disease

Indexed keywords

ASPARTYLGLUTAMYLVALYLASPARTIC ACID; BENZYLOXYCARBONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLTYROSYLVALYLALANYLASPARTYL CHLOROMETHYL KETONE; BENZYLOXYCARBONYLTYROSYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL DICHLOROBENZENE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BONGKREKIC ACID; CASPASE; CASPASE 3 INHIBITOR; CASPASE INHIBITOR; CYCLOSPORIN A; CYSTEINE PROTEINASE; DIZOCILPINE; IDN 5370; IDN 7866; ILEUCYLGLUTAMYLTHREONYLASPARTIC ACID; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; ISATIN; LEUCYLGLUTAMYLHISTIDYLASPARTIC ACID; LEVODOPA; M 791; M 826; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRALNACASAN; SULFONAMIDE; TRYPTOPHYLGLUTAMYLHISTIDYLASPARTIC ACID; TYROSYLVALYLALANYLASPARTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BRAIN ISCHEMIA; CELL DEATH; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; EXPERIMENTAL MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; BRAIN ISCHEMIA; CASPASES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 0036999911     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Stennicke HR, Salvesen GS: Properties of the caspases. Biochim Biophys Acta (1998) 1387:17-31.
2. Jacobson MD, Weil M, Raff MC: Programmed cell death in animal development. Cell (1997) 88:347-354.
3. Salvesen GS, Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell (1997) 91:443-446.
4. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR: The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell (1993) 75:641-652.
5. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M et al: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell (1996) 85:817-827.
6. Muzio M, Salvesen GS, Dixit VM: FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem (1997) 272:2952-2956.
7. Ni B, Wu X, Du Y, Su Y, Hamilton BE, Rockey PK, Rosteck PJ, Poirier GG, Paul SM: Cloning and expression of a rat brain interleukin-1β-converting enzyme (ICE)-related protease (IRP) and its possible role in apoptosis of cultured cerebellar granule neurons. J Neurosci (1997) 17:1561-1569.
8. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (1995) 376:37-43. Demonstration of caspase 3 involvement in apoptosis.
9. Orth K, O'Rourke K, Salvesen GS, Dixit VM: Molecular ordering of apoptotic mammalian CED-3/ICE-like proteases. J Biol Chem (1996) 271:20977-20980.
10. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem (1996) 271:16443-16446.
11. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen GS, Thomberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenclature. Cell (1995) 87:171. New designation as caspases for ICE-like proteases.
12. Nicholson DW, Thornberry NA: Caspases: Killer proteases. Trends Biochem Sci (1997) 22:299-306. Good review of caspase structure and substrate specificity.
13. Zhou Q, Snipas S, Orth K, Muzio M, Dixit VM, Salvesen GS: Target protease specificity of the viral serpin CrmA. Analysis of five caspases. J Biol Chem (1997) 272:7797-7800.
14. Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW: Substrate specificities of caspase family proteases. J Biol Chem (1997) 272:9677-9682.
15. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA: Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem (1998) 273:32608-32613.
16. Rano TA, Timkey T, Peterson EP, Rotonda J, Nicholson DW, Becker JW, Chapman KT, Thornberry NA: A combinatorial approach for determining protease specificities: Application to interleukin-1β converting enzyme (ICE). Chem Biol (1997) 4:149-155.
17. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem (1997) 272:17907-17911.
18. Margolin N, Raybuck SA, Wilson KP, Chen W, Fox T, Gu Y, Livingston DJ: Substrate and inhibitor specificity of interleukin-1β-converting enzyme and related caspases. J Biol Chem (1997) 272:7223-7228.
19. Denner L: Caspases in apoptotic death. Exp Opin Invest Drugs (1999) 8:37-50.
20. Ashwell S: Caspases: Recent advances in small molecule inhibitors. Exp Opin Ther Patents (2001) 11:1593-1603. Excellent review of caspase patent literature up to April 2001.
21. Lee D, Long SA, Adams JL, Chan G, Vaidya KS, Francis TA, Kikly K, Winkler JD, Sung C-M, Debouck C, Richardson S et al: Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. J Biol Chem (2000) 275:16007-16014.
22. Nicholson DW, Thornberry NA: Caspases: Killer proteases. Trends Biochem Sci (1997) 22:299-306.
23. Nicotera P: Caspase requirement for neuronal apoptosis and neurodegeneration. IUBMB Life (2000) 49:421-425.
24. Braun JS, Tuomanen EI, Cleveland JL: Neuroprotection by caspase inhibitors. Exp Opin Invest Drugs (1999) 8:1599-1610. Good, broad-based review of the evidence for caspase inhibitor neuroprotection in a number of neurodegenerative conditions.
25. Cotman CW, Su JH: Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol (1996) 6:493-506.
26. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW: Activated caspase-3 expression in Alzheimer's and aged control brain: Correlation with Alzheimer pathology. Brain Res (2001) 898:350-357.
27. Su JH, Anderson AJ, Cummings BJ, Cotman CW: Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport (1994) 5:2529-2533.
28. Mochizuki H, Goto K, Mori H, Mizuno Y: Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci (1996) 137:120-123.
29. Andersen JK: Does neuronal loss in Parkinson's disease involve programmed cell death? Bioessays (2001) 23:640-646.
30. Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI et al: Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA (2000) 97:2875-2880.
31. Viswanath V, Wu YQ, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang LC, Beal MF, Andersen JK: Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci (2001) 21:9519-9528.
32. Schulz JB, Gerhardt E: Apoptosis: Its relevance to Parkinson's disease. Clin Neurosci Research (2001) 1:427-433. Good reviews of the evidence for apoptosis in Parkinson's disease.
33. Ballard PA, Tetrud JW, Langston JW: Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology (1985) 35:949-956.
34. Heikkila RE, Hess A, Duvoisin RC: Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: Relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. Life Sci (1985) 36:231-236.
35. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC: Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci Lett (1985) 58:133-137.
36. Langston JW, Langston EB, Irwin I: MPTP-induced parkinsonism in human and non-human primates - Clinical and experimental aspects. Acta Neurol Scand Suppl (1984) 100:49-54.
37. Langston JW, Irwin I, Langston EB, Forno LS: Pargyline prevents MPTP-induced parkinsonism in primates. Science (1984) 225:1480-1482.
38. + in the substantia nigra: A key to neurotoxicity? Life Sci (1985) 36:207-212.
39. +): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett (1984) 48:87-92.
40. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci Lett (1994) 170:191-194.
41. Mytilineou C, Cohen G, Heikkila RE: 1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture. Neurosci Lett (1985) 57:19-24.
42. +) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. Neurosci Lett (1986) 72:215-220.
43. Turmel H, Hartmann A, Parain K, Douhou A, Srinivasan A, Agid Y, Hirsch EC: Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Mov Disord (2001) 16:185-189.
44. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Moautt-Prigent A, Ruberg M, Agid Y, Hirsch EC: Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci (2001) 21:2247-2255.
45. Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK: Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci (2001) 21:9519-9528.
46. Dodel RC, Du Y, Bales KR, Ling ZD, Carvey PM, Paul SM: Peptide inhibitors of caspase-3-like proteases attenuate 1-methyl-4-phenylpyridinum-induced toxicity of cultured fetal rat mesencephalic dopamine neurons. Neuroscience (1998) 86:701-707.
47. Bisland J, Roy S, Xanthoudakis S, Nicholson DW, Han Y, Grimm E, Hefti F, Harper SJ: Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci (2002) 22:2637-2649.
48. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC: Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21:2247-2255.
49. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R et al: Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nat Immunol (2000) 1:496-501.
50. + toxicity.
51. Lotharius J, Dugan LL, O'Malley KL: Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci (1999) 19:1284-1293.
52. +-induced dopaminergic neuronal cell death: Role of caspases, ROS, and JNK. J Neurosci Res (1999) 57:86-94.
53. Von Coelln R, Kugler S, Bahr M, Weller M, Dichgans J, Schulz JB: Rescue from death but not from functional impairment: Caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem (2001) 77:263-273.
54. Eberhardt O, Coelln RV, Kugler S, Lindenau J, Rathke-Hartlieb S, Gerhardt E, Haid S, Isenmann S, Gravel C, Srinivasan A, Bahr M et al: Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci (2000) 20:9126-9134. Demonstration that caspase inhibition by XIAP overexpression spares cell somata in the MPTP mouse PD model, but additional trophic support is required to spare striatal innervation.
55. Cutillas B, Espejo M, Gil J, Ferrer I, Ambrosio S: Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. Neuroreport (1999) 10:2605-2608.
56. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, Beal MF: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci (1998) 18:8145-8152.
57. Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R, Bernard O: Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA (1998) 95:5789-5794.
58. Crocker SJ, Wigle N, Liston P, Thompson CS, Lee C, Xu DG, Roy S, Nicholson DW, Park DS, MacKenzie A, Korneluck RG, Robertson GS: NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. Eur J Neurosci (2001) 14:391-400.
59. Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR Jr, Friedlander RM, Beal MF: Transgenic mice expressing a dominant negative mutant interleukin-1β converting enzyme show resistance to MPTP neurotoxicity. Neuroreport (1999) 10:635-638.
60. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB: Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA (2001) 98:10433-10438.
61. Loddick SA, MacKenzie A, Rothwell NJ: An ICE inhibitor, (Z)-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport (1996) 7:1465-1468. First demonstration of neuroprotection by caspase inhibition in an ischemic model.
62. Hara H, Friedlander RM, Gagliardini V, Ayata C, Fink K, Huang Z, Shimizu-Sasamata M, Yuan J, Moskowitz MA: Inhibition of interleukin 1β converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA (1997) 94:2007-2012.
63. Cheng Y, Deshmukth M, D'Costa A, Demaro JA, Gidday JM, Shah A, Sun Y, Jacquin MF, Johnson EM, Holtzman DM: Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest (1998) 101:1992-1999.
64. Wiessner C, Sauer D, Alaimo D, Allegrini PR: Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell Mol Biol (2000) 46:53-62.
65. Schielke GP, Yang GY, Shivers BD, Betz AL: Reduced ischemic brain injury in interleukin-1β converting enzyme-deficient mice. J Cereb Blood Flow Metab (1998) 18:180-185.
66. Liu XH, Kwon D, Schielke GP, Yang GY, Silverstein FS, Barks JD: Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J Cereb Blood Flow Metab (1999) 19:1099-1108.
67. Friedlander RM, Gagliardini V, Hara H, Fink KB, Li W, Macdonald G, Fishman MC, Greenberg AH, Moskowitz MA, Yuan J: Expression of a dominant negative mutant of interleukin-1β converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Exp Med (1997) 185:933-940.
68. Hara H, Fink K, Endres M, Friedlander RM, Gagliardini V, Yuan J, Moskowitz MA: Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cereb Blood Flow Metab (1997) 17:370-375.
69. Rabuffetti M, Sciorati C, Tarozzo G, Clementi E, Manfredi AA, Beltramo M: Inhibition of caspase-1-like activity by Ac-Tyr-Val-Ala-Asp-chloromethyl ketone induces long-lasting neuroprotection in cerebral ischemia through apoptosis reduction and decrease of proinflammatory cytokines. J Neurosci (2000) 20:4398-4404.
70. Touzani O, Boutin H, LeFeuvre R, Paker L, Miller A, Luheshi G, Rothwell N: Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci (2002) 22:38-43.
71. Fink K, Zhu J, Namura S, Shimizu-Sasamata M, Endres M, Ma J, Dalkara T, Yuan J, Moskowitz MA: Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab (1998) 18:1071-1076.
72. Deckwerth TL, Adams LM, Wiessner C, Allegrini P, Rudin M, Sauter A, Hengerer B, Sayers RO, Rovelli G, Aja T, May R et al: Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. Drug Dev Res (2001) 52:579-586. Peripheral administration of a novel caspase inhibitor developed by Idun Pharmaceuticals attenuates cerebral ischemic damage.
73. Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A et al: Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J Biol Chem (2002) 277(33):30128-30136.
74. Xu DG, Crocker SJ, Doucet JP, St. Jean M, Tamai K, Hakim AM, Ikeda JE, Liston P, Thompson CS, Korneluk RG, MacKenzie A, Robertson GS: Evaluation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat Med (1997) 3:997-1004.
75. Xu D, Bureau Y, McIntyre DC, Nicholson DW, Liston P, Zhu Y, Fong WG, Crocker SJ, Korneluk RG, Robertson GS: Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J Neurosci (1999) 19:5026-5033.
76. Ma J, Endres M, Moskowitz MA: Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice. Br J Pharmacol (1998) 124:756-762.
77. Gillardon F, Kiprianova I, Sandkuhler J, Hossmann KA, Spranger M: Inhibition of caspases prevents cell death of hippocampal CA1 neurons, but not impairment of hippocampal long-term potentiation following global ischemia. Neuroscience (1999) 93:1219-1222.
78. Loetscher H, Niederhauser O, Kemp J, Gill R: Is caspase-3 inhibition a valid therapeutic strategy in cerebral ischemia? Drug Disc Today (2001) 6:671-680. Review of evidence against caspase inhibition as a therapeutic strategy in cerebral ischemia.
79. Harada J, Sugimoto M: Inhibitors of interleukin-1β-converting enzyme-family proteases (caspases) prevent apoptosis without affecting decreased cellular ability to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in cerebellar granule neurons. Brain Res (1998) 793:231-243.
80. Tolkovsky AM, Xue L, Fletcher GC, Borutaite V: Mitochondrial disappearance from cells: A clue to the role of autophagy in programmed cell death and disease? Biochimie (2002) 84:233-240.
81. Xue L, Fletcher GC, Tolkovsky AM: Mitochondria are selectively eliminated from eukaryotic cells after blockade of caspases during apoptosis. Curr Biol (2001) 11:361-365.
82. Xue L, Fletcher GC, Tolkovsky AM: Autophagy is activated by apoptotic signalling in sympathetic neurons: An alternative mechanism of death execution. Mol Cell Neurosci (1999) 14:180-198.
83. Schwab BL, Guerini D, Didszun C, Bano D, Ferrando-May E, Fava E, Tam J, Xu D, Xanthoudakis S, Nicholson DW, Carafoli E, Nicotera P: Cleavage of plasma membrane calcium pumps by caspases: A link between apoptosis and necrosis. Cell Death Differ (2002) 9:818-831.
84. Leist M, Jaattela M: Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol (2001) 2:589-598.
85. Nicotera P, Leist M, Fava E, Berliocchi L, Volbracht C: Energy requirement for caspase activation and neuronal cell death. Brain Pathol (2000) 10:276-282.
86. Holtzman DM, Deshmukh M: Caspases: A treatment target for neurodegenerative disease? Nat Med (1997) 3:954-955.
87. Enari M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature (1995) 375:78-81.
88. Muzio M, Salvesen GS, Dixit VM: FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem (1997) 272:2952-2956.
89. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES: Molecular ordering of the Fas-apoptotic pathway: The Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc Natl Acad Sci USA (1996) 93:14486-14491.
90. Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW: CPP32/apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem (1996) 271:1841-1844.
91. Susin SA, Zamzami N, Kroemer G: Mitochondria as regulators of apoptosis: Doubt no more. Biochim Biophys Acta (1998) 1366:151-165.
92. Green DR, Reed JC: Mitochondria and apoptosis. Science (1998) 281:1309-1312.
93. Yang JC, Cortopassi GA: Induction of the mitochondrial permeability transition causes release of the apoptogenic factor cytochrome C. Free Radic Biol Med (1998) 24:624-631.
94. Ichas F, Mazat JP: From calcium signaling to cell death: Two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta (1998) 1366:33-50.
95. Petronilli V, Penzo D, Scorrano L, Bermardi P, Di Lisa F: The mitochondrial permeability transition, release of cytochrome C and cell death - Correlation with the duration of pore openings in situ. J Biol Chem (2001) 276:12030-12034.
96. Bossy-Wetzel E, Newmeyer DD, Green DR: Mitochondrial cytochrome C release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J (1998) 17:37-49.
97. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome C from mitochondria blocked. Science (1997) 275:1129-1132.
98. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K et al: Inhibition of Bax channel-forming activity by Bcl-2. Science (1997) 277:370-372.
99. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome C from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science (1997) 275:1132-1136.
100. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: Requirements for dATP and cytochrome C. Cell (1996) 86:147-157.
101. Pan G, Humke EW, Dixit VM: Activation of caspases triggered by cytochrome C in vitro. FEBS Lett (1998) 426:151-154.